NCT00822861View on ClinicalTrials.gov

Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma

PHASE2CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions

Asthma

Interventions

DRUG

TPI ASM8

4 mg/mL, 1 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 2 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 4 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 8 mg OD for 4 days

Trial Locations (1)

L8N 3Z5

McMaster University, Hamilton

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Syntara

INDUSTRY

NCT00822861 - Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma | Biotech Hunter | Biotech Hunter